🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “msc” Clear

  1. MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis

    phase 2 mab completed

    1 trial

  2. Medical Collagen Membrane with MSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Wounds

    phase 2 other active

    1 trial

  3. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 mab completed

    1 trial

  4. Placebo vials contain 4.5 ml of storage solution only (2.5 ml albumin 20%, 1.1 ml normal saline solution, 0.45 ml Citrate dextrose solution, 0.45 ml Dimethyl sulfoxide). Placebo and MSC vials are indistinguishable in appearance after thawing. There are no observable differences between treatments that could potentially compromise the blind., Mesenchymal stromal cells

    Fondazione Telethon ETS

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  5. UC-MSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  6. UC-MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cirrhosis Due to Hepatitis B

    phase 2 mab active

    1 trial

  7. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  8. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial

  9. allogeneic human mesenchymal stem cells (hMSCs)

    United Therapeutics Europe Ltd

    Non-ischemic Dilated Cardiomyopathy

    phase 2 mab active

    1 trial

  10. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  11. Allogeneic (MSC's) Application to the Burn Wounds

    United Therapeutics Europe Ltd

    Skin Burn Degree Second

    phase 1 mab completed

    1 trial

  12. Allogeneic MSC

    United Therapeutics Europe Ltd

    Mesenchymal Stromal Cells

    phase 1 mab completed

    1 trial

  13. Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles (hUCMSC-EVs)

    Shanghai Zhongshan Hospital

    Interstitial Lung Disease (ILD)

    phase 1 mab active

    1 trial

  14. MCA-derived MSC therapy in renal transplant recipients

    Disc Medicine

    Rejection transplanted kidney, BPAR

    phase 1 other active

    1 trial

  15. MSC-derived exosomes

    Regeneron Ireland Designated Activity Company (DAC)

    Long COVID-19 Syndrome

    phase 1 mab active

    1 trial

  16. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  17. MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab active

    1 trial

  18. MSCs-derived exosomes

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronavirus

    phase 1 mab completed

    1 trial

  19. NeuroRegen scaffold with BMMCs or MSCs transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injury

    phase 1 mab active

    1 trial

  20. UCMSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopleural Fistula

    phase 1 mab active

    1 trial

  21. human Mesenchymal Stem Cell (MSC) infusion therapy

    CytoMed Therapeutics Ltd

    Aging Well

    phase 1 mab active

    1 trial

  22. ucMSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchopulmonary Dysplasia

    phase 1 mab active

    1 trial

  23. mesenchymal stromal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    MSC

    approved mab active

    1 trial

  24. UC-MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    2019 Novel Coronavirus Pneumonia

    mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources